

OPTIONS FOR H1N1

**OPTION 1. MAINTAIN CURRENT VACCINE STRAIN,
A/NEW CALEDONIA/20/99**

**PRO MANUFACTURING IS WORKED OUT AND
YIELD IS PREDICTABLE**

**MOST OF THE VIRUSES THIS YEAR ARE
A/NEW CALEDONIA/20/99-LIKE BY ANTIGENIC
CHARACTERIZATION OF THE HEMAGGLUTININ**

**CON RELATIVELY FEW RECENT STRAINS FOR
ANALYSIS**

OPTIONS FOR H1N1

OPTION 2. CHANGE CURRENT VACCINE STRAIN TO A STRAIN MORE REPRESENTATIVE OF CURRENTLY CIRCULATING VIRUSES

PRO A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

CON A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN

NO NEW STRAINS HAVE BEEN IDENTIFIED AND MANUFACTURING ISSUES HAVE NOT BEEN INVESTIGATED

OPTIONS FOR H1N1

OPTION 3. POSTPONE DECISION

PRO **A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS**

CON **NO NEW DATA APPEARS FORTHCOMING**

OPTIONS FOR H3N2

OPTION 1. MAINTAIN CURRENT VACCINE STRAIN, A/PANAMA/2007/99

**PRO MANUFACTURING IS WORKED OUT AND
YIELD IS PREDICTABLE**

**MOST OF THE VIRUSES THIS YEAR ARE
A/PANAMA/2007/99-LIKE BY ANTIGENIC
CHARACTERIZATION OF THE HEMAGGLUTININ**

**CON INFORMATION ABOUT NEWEST STRAINS IS NOT
YET ANALYZED**

**H3N2 INFLUENZA VIRUSES ARE OFTEN
RESPONSIBLE FOR SIGNIFICANT MORBIDITY AND
MORTALITY**

OPTIONS FOR H3N2

OPTION 2. CHANGE CURRENT VACCINE STRAIN TO A STRAIN MORE REPRESENTATIVE OF CURRENTLY CIRCULATING VIRUSES

PRO A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

H3N2 INFLUENZA VIRUSES OFTEN RESPONSIBLE FOR SIGNIFICANT MORBIDITY AND MORTALITY

CON INFORMATION ABOUT NEWEST STRAINS IS NOT YET ANALYZED

A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN

NO NEW STRAINS HAVE BEEN EVALUATED FOR MANUFACTURING ISSUES

OPTIONS FOR H3N2

OPTION 3. POSTPONE DECISION

PRO **POSTPONING DECISION WOULD PROVIDE TIME TO ANALYZE NEWLY COLLECTED STRAINS**

A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

H3N2 INFLUENZA VIRUSES OFTEN RESPONSIBLE FOR SIGNIFICANT MORBIDITY AND MORTALITY

CON **A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN**

NO NEW STRAINS HAVE BEEN IDENTIFIED AND MANUFACTURING ISSUES HAVE NOT BEEN INVESTIGATED

OPTIONS FOR B

**OPTION 1. RETAIN THE CURRENT VACCINE STRAINS,
B/VICTORIA/504/2000 OR B/GUANGDONG/120/2000**

**PRO MANUFACTURING IS WELL DEFINED AND
PREDICTABLE**

**CON SOME NEW VARIANT STRAINS HAVE BEEN
IDENTIFIED IN THE VACCINE HA LINEAGE**

**STRAINS IN THE B/SHANGDONG/7/97 HA LINEAGE
ARE APPEARING IN INCREASING NUMBERS AND
IN NEW REGIONS**

**SOME INFLUENZA B STRAINS, PARTICULARLY
THOSE IN THE B/SHANGDONG/7/97 HA LINEAGE,
ARE NOT WELL INHIBITED BY POST-INFECTION
AND POST-IMMUNIZATION ANTISERA**

OPTIONS FOR B

OPTION 2. CHANGE CURRENT VACCINE STRAIN TO ANOTHER INFLUENZA B STRAIN

PRO VACCINES MIGHT PROVIDE BROADER COVERAGE FOR CURRENT INFLUENZA B VIRUSES

SEVERAL CANDIDATE STRAINS HAVE BEEN IDENTIFIED AND ARE BEING EXAMINED FOR SUITABILITY BY MULTIPLE MANUFACTURERS

CON NEW STRAINS MAY CAUSE DIFFICULTIES IN MANUFACTURING UNTIL ALL PROCESS PARAMETERS CAN BE OPTIMIZED

OPTIONS FOR B

OPTION 3. POSTPONE DECISION

PRO POSTPONING DECISION WOULD PROVIDE TIME TO FOR ADDITIONAL EVALUATIONS OF INFLUENZA B STRAINS

A MORE RECENT STRAIN MIGHT PROVIDE A CLOSER MATCH WITH THE HEMAGGLUTININ AND NEURAMINIDASE OF CONTEMPORARY STRAINS

CON A NEW STRAIN MAY NOT PROVIDE SUPERIOR COVERAGE COMPARED TO CURRENT VACCINE STRAIN